JP2017536114A5 - - Google Patents

Download PDF

Info

Publication number
JP2017536114A5
JP2017536114A5 JP2017524014A JP2017524014A JP2017536114A5 JP 2017536114 A5 JP2017536114 A5 JP 2017536114A5 JP 2017524014 A JP2017524014 A JP 2017524014A JP 2017524014 A JP2017524014 A JP 2017524014A JP 2017536114 A5 JP2017536114 A5 JP 2017536114A5
Authority
JP
Japan
Prior art keywords
vnar
amino acid
encode
domain
codons
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017524014A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017536114A (ja
JP6734271B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2015/002086 external-priority patent/WO2016070959A1/en
Publication of JP2017536114A publication Critical patent/JP2017536114A/ja
Publication of JP2017536114A5 publication Critical patent/JP2017536114A5/ja
Application granted granted Critical
Publication of JP6734271B2 publication Critical patent/JP6734271B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017524014A 2014-11-03 2015-10-21 二重特異性サメ抗体可変ドメインの製造方法およびそれらの使用 Expired - Fee Related JP6734271B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14003700 2014-11-03
EP14003700.3 2014-11-03
PCT/EP2015/002086 WO2016070959A1 (en) 2014-11-03 2015-10-21 Methods for generating bispecific shark variable antibody domains and use thereof

Publications (3)

Publication Number Publication Date
JP2017536114A JP2017536114A (ja) 2017-12-07
JP2017536114A5 true JP2017536114A5 (enExample) 2018-11-29
JP6734271B2 JP6734271B2 (ja) 2020-08-05

Family

ID=51945671

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017524014A Expired - Fee Related JP6734271B2 (ja) 2014-11-03 2015-10-21 二重特異性サメ抗体可変ドメインの製造方法およびそれらの使用

Country Status (8)

Country Link
US (1) US11001640B2 (enExample)
EP (1) EP3215531A1 (enExample)
JP (1) JP6734271B2 (enExample)
CN (1) CN107074961A (enExample)
AU (1) AU2015342264B2 (enExample)
CA (1) CA2966397A1 (enExample)
IL (1) IL252008A0 (enExample)
WO (1) WO2016070959A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018031424A1 (en) * 2016-08-06 2018-02-15 Ossianix, Inc. In vivo methods for selecting peptides that cross the blood brain barrier, related compositions and methods of use
EP4491234A3 (en) 2017-02-08 2025-04-09 Dragonfly Therapeutics, Inc. Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer
BR112019017197A2 (pt) 2017-02-20 2020-04-14 Dragonfly Therapeutics, Inc. proteínas que se ligam a her2, nkg2d e cd16
KR20200037388A (ko) * 2017-08-16 2020-04-08 드래곤플라이 쎄라퓨틱스, 인크. Nkg2d, cd16, 및 egfr, hla-e, ccr4 또는 pd-l1에 결합하는 단백질
AU2019218125B2 (en) 2018-02-08 2025-03-13 Dragonfly Therapeutics, Inc. Combination therapy of cancer involving multi-specific binding proteins that activate natural killer cells
PE20220278A1 (es) 2018-02-08 2022-02-25 Dragonfly Therapeutics Inc Dominios variables de anticuerpos que se dirigen al receptor nkg2d
TW201942134A (zh) 2018-02-20 2019-11-01 美商蜻蜓醫療公司 結合cd33、nkg2d及cd16之多特異性結合蛋白及使用方法
EA202091888A1 (ru) 2018-08-08 2020-10-23 Драгонфлай Терапьютикс, Инк. Вариабельные домены антител, нацеленные на рецептор nkg2d
KR20250112921A (ko) 2018-08-08 2025-07-24 드래곤플라이 쎄라퓨틱스, 인크. Nkg2d, cd16 및 종양 관련 항원에 결합하는 단백질
EA202190468A1 (ru) 2018-08-08 2021-07-06 Драгонфлай Терапьютикс, Инк. Мультиспецифические связывающие белки, которые связывают bcma, nkg2d и cd16, и способы их применения
WO2020056327A1 (en) 2018-09-14 2020-03-19 Ossianix, Inc. Tfr-specific binding moieties and transcytosis method to select vnars that cross cellular barriers
EP4146271A4 (en) 2020-05-06 2024-09-04 Dragonfly Therapeutics, Inc. PROTEINS THAT BIND NKG2D, CD16 AND CLEC12A
CN112301431B (zh) * 2020-08-12 2023-01-31 华东理工大学 基于鲨鱼抗体可变区v-nar的噬菌体文库及其构建方法
US12377144B2 (en) 2021-03-03 2025-08-05 Dragonfly Therapeutics, Inc. Methods of treating cancer using multi-specific binding proteins that bind NKG2D, CD16 and a tumor-associated antigen
CN112940120B (zh) * 2021-05-14 2021-08-17 深圳海创生物技术有限公司 降钙素原单域抗体及其应用和试剂盒
CN118475603A (zh) * 2021-11-03 2024-08-09 香港城市大学深圳研究院 高亲和力抗EGFP和抗SARS-CoV-2 vNAR单域抗体及其用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100976743B1 (ko) 2001-05-24 2010-08-19 지모제넥틱스, 인코포레이티드 Taci-면역글로불린 융합 단백질
AP2012006359A0 (en) * 2010-03-03 2012-08-31 Boehringer Ingelheim Int Biparatopic abeta binding polypeptides
RU2608640C2 (ru) * 2010-08-16 2017-01-23 Новиммун С.А. Способы получения мультиспецифичных и мультивалентных антител
WO2013167883A1 (en) 2012-05-07 2013-11-14 The University Court Of The University Of Aberdeen Single domain binding molecule
JP6616284B2 (ja) * 2013-04-23 2019-12-04 ザ ユニバーシティ コート オブ ザ ユニバーシティ オブ アバディーン 特異的結合分子の人工ライブラリー

Similar Documents

Publication Publication Date Title
JP2017536114A5 (enExample)
JP2017114866A5 (enExample)
IL275270A (en) Recombinant scavenger cell surface proteins
HRP20201634T1 (hr) Monoklonsko protutijelo protiv interleukina-31
JP2016029056A5 (enExample)
JP2016026303A5 (enExample)
ES2641294T3 (es) Nuevo anticuerpo para el diagnóstico y/o el pronóstico del cáncer
HRP20250850T1 (hr) Antitijela protiv claudina 18.2 korisna u dijagnozi raka
AR108066A1 (es) Receptores quiméricos para cll-1 y métodos de uso de los mismos
WO2018057735A8 (en) Antibodies for siglec-15 and methods of use thereof
JP2019500862A5 (enExample)
IL273196B1 (en) Claudin 6 antibodies and methods of cancer treatment
JP2012143232A5 (enExample)
RU2018137419A (ru) Связывающиеся с cd38 и pd-l1 молекулы
JP2015529826A5 (enExample)
EA201791666A1 (ru) Антитела к cd3, антитела к cd123 и биспецифические антитела, которые специфически связываются с cd3 и/или cd123
JP2013535191A5 (enExample)
JP2014158485A5 (enExample)
JP2015519344A5 (enExample)
JP2016536322A5 (enExample)
JP2016502843A5 (enExample)
JP2018528786A5 (enExample)
JP2013509878A5 (enExample)
JP2017538412A5 (enExample)
JP2017522886A5 (enExample)